Home/Vivet Therapeutics/Jean-Philippe Combal
JC

Jean-Philippe Combal

CEO & Co-founder

Vivet Therapeutics

Vivet Therapeutics Pipeline

DrugIndicationPhase
VTX-PIDDepletion of Neutralizing Antibodies against AAVPhase 1/2
VTX-801Wilson's DiseasePhase 1/2
VTX-806Cerebrotendinous Xanthomatosis (CTX)Preclinical
VTX-802Progressive Familial Intrahepatic Cholestasis Type 2 (PFIC2)Preclinical